← Back to all trials
Recruiting
NCT05645302
Intensive Monitoring Scheme of Lidocaine Cataplasms
Conditions: Adverse Reaction to Drug
Sex: All
Enrollment: 200
Sponsor: Qianfoshan Hospital
Location: China
Summary
In this center, retrospective research methods are used to collect data.
Patients who had used Lidocaine Cataplasms at least once were included consecutively.
Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).
Eligibility Criteria
Inclusion Criteria:All patients receiving Lidocaine Cataplasms from January 1, 2021 to April 1, 2022.Exclusion Criteria:Unable to obtain complete medication information.
Source: ClinicalTrials.gov (NCT05645302). StuddyBuddy aggregates publicly available trial information.